2023 ESMO Congress Reveals YOUNGBC-21 Study Results
Editor's note: HER2-positive metastatic breast cancer (HER2+ MBC) has seen the emergence of several new drugs, but the combination of Pyrotinib with dual targeting therapy remains the preferred first-line option.…
